WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 526692
Description: A-192621 is an endothelin-B antagonist. A-192621 markedly enhanced MAP, TPR, and mesenteric, and the renal constrictor effects of ET-1. A-192621 was more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1.
MedKoo Cat#: 526692
Chemical Formula: C33H38N2O6
Exact Mass: 558.273
Molecular Weight: 558.675
Elemental Analysis: C, 70.95; H, 6.86; N, 5.01; O, 17.18
Synonym: A-192621; A 192621; A192621; A-192621-1; A-192621.1.
IUPAC/Chemical Name: (2R,3R,4S)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-((2,6-diethylphenyl)amino)-2-oxoethyl)-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid
InChi Key: LQEHCKYYIXQEBM-FUKIBTTHSA-N
InChi Code: InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1
SMILES Code: O=C([C@H]1[C@H](C2=CC=C(OCCC)C=C2)N(CC(NC3=C(CC)C=CC=C3CC)=O)C[C@@H]1C4=CC=C(OCO5)C5=C4)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 558.675 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Wessale JL, Adler AL, Novosad EI, Calzadilla SV, Dayton BD, Marsh KC, Winn M,
Jae HS, von Geldern TW, Opgenorth TJ, Wu-Wong JR. Pharmacology of endothelin
receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo
studies. Clin Sci (Lond). 2002 Aug;103 Suppl 48:112S-117S. PubMed PMID: 12193067.
2: Wu-Wong JR, Dixon DB, Chiou WJ, Sorensen BK, Liu G, Jae HS, Tasker A, von
Geldern TW, Winn M, Opgenorth TJ. Pharmacology of endothelin receptor antagonists
ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond). 2002
Aug;103 Suppl 48:107S-111S. PubMed PMID: 12193066.
3: Leung SW, Lim SL, Pang CC, Man RY. Use of A-192621 and IRL-2500 to unmask the
mesenteric and renal vasodilator role of endothelin ET(B) receptors. J Cardiovasc
Pharmacol. 2002 Apr;39(4):533-43. PubMed PMID: 11904527.
4: Cullen JP, Bell D, Kelso EJ, McDermott BJ. Use of A-192621 to provide evidence
for involvement of endothelin ET(B)-receptors in endothelin-1-mediated
cardiomyocyte hypertrophy. Eur J Pharmacol. 2001 Apr 13;417(3):157-68. PubMed
5: Brodsky S, Abassi Z, Wessale J, Ramadan R, Winaver J, Hoffman A. Effects of
A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic
responses to endothelin-1. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S311-3.
PubMed PMID: 11078406.